Fenbutyramide

Fenbutyramide

SCHEMBL1478462

CC[C@H](C(N)=O)c1ccccc1

nearest known ligand 0.63

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ EPHX1 P07099 1/20 0.63
▸ LMNA P02545 3/20 0.56
▸ HSD17B10 Q99714 1/20 0.56
▸ ALDH1A1 P00352 1/20 0.51
▸ POLB P06746 1/20 0.51
▸ CRHBP P24387 2/20 0.50
▸ CRHR2 Q13324 2/20 0.50
▸ KCNQ2 O43526 2/20 0.50
▸ HTT P42858 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ GAA P10253 2/20 0.49
▸ KDM4A O75164 1/20 0.49
▸ BCHE P06276 1/20 0.49
▸ MAPT P10636 1/20 0.49
▸ MEN1 O00255 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ RECQL P46063 1/20 0.48
▸ TDP1 Q9NUW8 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fenbutyramide SCHEMBL232920 1.00 EPHX1 (0.63) EPHX1LMNAHSD17B10ALDH1A1POLB
Fenbutyramide SCHEMBL1477997 1.00 EPHX1 (0.63) EPHX1LMNAHSD17B10ALDH1A1POLB
Fenbutyramide SCHEMBL15995561 0.98 EPHX1 (0.61) EPHX1LMNAHSD17B10ALDH1A1POLB
SCHEMBL4935067 0.85 LMNA (0.61) LMNAHSD17B10ALDH1A1POLBCRHBP
SCHEMBL2183709 0.84 EPHX1 (0.59) EPHX1LMNAHSD17B10KCNQ2SMN1; SMN2
SCHEMBL15828137 0.84 LMNA (0.53) EPHX1LMNAHSD17B10ALDH1A1POLB
SCHEMBL18098100 0.83 EPHX1 (0.54) EPHX1LMNAHSD17B10ALDH1A1POLB
SCHEMBL67237 0.83 LMNA (0.59) LMNAHSD17B10ALDH1A1POLBCRHBP
SCHEMBL1715 0.83 LMNA (0.59) LMNAHSD17B10ALDH1A1POLBCRHBP
SCHEMBL65737 0.83 LMNA (0.59) LMNAHSD17B10ALDH1A1POLBCRHBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110144033-A1 Proteasome Inhibitors and Methods of Using the Same CEPHALON, INC. (US) 2011-06-16 — — US claimed
US-7915236-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2011-03-29 — — US claimed
EP-1660507-B9 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-03-24 — — EP claimed
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2009-11-26 — — US claimed
EP-1660507-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2009-08-05 — — EP claimed
EP-1660507-A2 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2006-05-31 — — EP claimed
US-20050107307-A1 Proteasome inhibitors and methods of using the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-19 — — US claimed
WO-2005021558-A2 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2005-03-10 — — WO claimed
WO-2017216726-A1 SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2017-12-21 — — WO disclosed
EP-2685982-B1 PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES BRISTOL MYERS SQUIBB CO (US) 2017-07-05 — — EP disclosed
EP-1660507-B2 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME MILLENNIUM PHARM INC (US) 2017-01-04 — — EP disclosed
US-9233115-B2 Proteasome inhibitors and methods of using the same MILLENNIUM PHARMACEUTICALS INC. (US) 2016-01-12 — — US disclosed
US-20140088042-A1 Proteasome Inhibitors And Methods Of Using The Same CEPHALON, INC. (US) 2014-03-27 — — US disclosed
US-8039506-B2 Bicyclic lactam factor VIIa inhibitors useful as anticoagulants BRISTOL-MYERS SQUIBB COMPANY (US) 2011-10-18 — — US disclosed
EP-1660507-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2009-08-05 — — EP disclosed
WO-2008079759-A1 BICYCLIC LACTAM FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS BRISTOL-MYERS SQUIBB COMPANY (US) 2008-07-03 — — WO disclosed
US-20070149779-A1 PRIMIDONE PROCESS AND COMPOSITIONS DR. REDDY'S LABORATORIES, INC. 2007-06-28 — — US disclosed
US-7109243-B2 Inhibitors of cathepsin S IRM LLC (BM) 2006-09-19 — — US disclosed
US-20050107307-A1 Proteasome inhibitors and methods of using the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-19 — — US disclosed
CN-1155535-A Adduct salts of novel substituted benzyl amines and process for optically resolving them AJINOMOTO KK (JP) 1997-07-30 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME PSMB11, PSMB5, PSMB6 EPHX1 2993/4885LMNA 770/4885HSD17B10 2988/4885
US-20050107307-A1 Proteasome inhibitors and methods of using the same PSMB11, PSMB5, PSMB6 EPHX1 2993/4885LMNA 770/4885HSD17B10 2988/4885
US-20070149779-A1 PRIMIDONE PROCESS AND COMPOSITIONS DPYD, SDHA, NDUFS5 EPHX1 1781/4885LMNA 733/4885HSD17B10 741/4885
US-20140088042-A1 Proteasome Inhibitors And Methods Of Using The Same PSMB11, PSMB5, PSMB6 EPHX1 2993/4885LMNA 770/4885HSD17B10 2988/4885
US-20110144033-A1 Proteasome Inhibitors and Methods of Using the Same PSMB11, PSMB5, PSMB6 EPHX1 2993/4885LMNA 770/4885HSD17B10 2988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback